Verrica Pharmaceuticals Inc.
VRCA
$5.23
-$0.12-2.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.72% | -19.45% | 47.66% | 187.45% | 61.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.72% | -19.45% | 47.66% | 187.45% | 61.61% |
| Cost of Revenue | -41.65% | -40.57% | -22.57% | 157.31% | 109.36% |
| Gross Profit | 80.70% | 48.46% | 37.32% | -146.36% | -176.75% |
| SG&A Expenses | -37.55% | -13.47% | 24.35% | 96.84% | 302.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.15% | -25.22% | 7.40% | 62.03% | 187.55% |
| Operating Income | 50.65% | 25.91% | -4.14% | -53.81% | -233.74% |
| Income Before Tax | 44.09% | 18.27% | -14.31% | -75.92% | -271.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.09% | 18.27% | -14.31% | -75.92% | -271.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.09% | 18.27% | -14.31% | -75.92% | -271.06% |
| EBIT | 50.65% | 25.91% | -4.14% | -53.81% | -233.74% |
| EBITDA | 51.04% | 26.35% | -3.52% | -53.59% | -237.85% |
| EPS Basic | 55.79% | 31.22% | -5.04% | -69.91% | -250.93% |
| Normalized Basic EPS | 54.53% | 29.06% | -9.04% | -64.82% | -265.02% |
| EPS Diluted | 55.80% | 31.19% | -5.07% | -69.59% | -249.50% |
| Normalized Diluted EPS | 54.53% | 29.06% | -9.04% | -64.82% | -265.01% |
| Average Basic Shares Outstanding | 63.91% | 38.25% | 14.22% | 5.67% | 8.82% |
| Average Diluted Shares Outstanding | 63.93% | 38.25% | 14.22% | 5.67% | 8.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |